vs
Cellectis S.A.（CLLS）与EXELIXIS, INC.（EXEL）财务数据对比。点击上方公司名可切换其他公司
EXELIXIS, INC.的季度营收约是Cellectis S.A.的63.0倍（$598.7M vs $9.5M）。EXELIXIS, INC.净利率更高（40.8% vs -265.9%，领先306.7%）。Cellectis S.A.同比增速更快（375.0% vs 5.6%）。EXELIXIS, INC.自由现金流更多（$332.4M vs $27.6M）
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
Exelixis是一家总部位于美国加利福尼亚州阿拉米达的基因组学药物研发企业，专注于创新抗肿瘤药物开发，旗下产品Cometriq已获美国FDA批准用于治疗甲状腺髓样癌，在其余多种转移性癌症治疗领域也已展现出良好临床活性。
CLLS vs EXEL — 直观对比
营收规模更大
EXEL
是对方的63.0倍
$9.5M
营收增速更快
CLLS
高出369.3%
5.6%
净利率更高
EXEL
高出306.7%
-265.9%
自由现金流更多
EXEL
多$304.7M
$27.6M
损益表 — Q2 2024 vs Q4 2026
| 指标 | | |
|---|---|---|
| 营收 | $9.5M | $598.7M |
| 净利润 | $-25.3M | $244.5M |
| 毛利率 | — | 95.6% |
| 营业利润率 | -181.1% | 39.3% |
| 净利率 | -265.9% | 40.8% |
| 营收同比 | 375.0% | 5.6% |
| 净利润同比 | -51.9% | 74.8% |
| 每股收益（稀释后） | $-0.28 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLSEXEL
| Q1 26 | — | $598.7M | ||
| Q4 25 | — | $597.8M | ||
| Q3 25 | — | $568.3M | ||
| Q2 25 | — | $555.4M | ||
| Q1 25 | — | $566.8M | ||
| Q3 24 | — | $539.5M | ||
| Q2 24 | $9.5M | $637.2M | ||
| Q1 24 | — | $425.2M |
净利润CLLSEXEL
| Q1 26 | — | $244.5M | ||
| Q4 25 | — | $193.6M | ||
| Q3 25 | — | $184.8M | ||
| Q2 25 | — | $159.6M | ||
| Q1 25 | — | $139.9M | ||
| Q3 24 | — | $118.0M | ||
| Q2 24 | $-25.3M | $226.1M | ||
| Q1 24 | — | $37.3M |
毛利率CLLSEXEL
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q3 24 | — | 96.8% | ||
| Q2 24 | — | 97.2% | ||
| Q1 24 | — | 95.0% |
营业利润率CLLSEXEL
| Q1 26 | — | 39.3% | ||
| Q4 25 | — | 39.6% | ||
| Q3 25 | — | 37.6% | ||
| Q2 25 | — | 33.6% | ||
| Q1 25 | — | 28.8% | ||
| Q3 24 | — | 25.2% | ||
| Q2 24 | -181.1% | 43.3% | ||
| Q1 24 | — | 6.9% |
净利率CLLSEXEL
| Q1 26 | — | 40.8% | ||
| Q4 25 | — | 32.4% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 28.7% | ||
| Q1 25 | — | 24.7% | ||
| Q3 24 | — | 21.9% | ||
| Q2 24 | -265.9% | 35.5% | ||
| Q1 24 | — | 8.8% |
每股收益（稀释后）CLLSEXEL
| Q1 26 | — | $0.89 | ||
| Q4 25 | — | $0.69 | ||
| Q3 25 | — | $0.65 | ||
| Q2 25 | — | $0.55 | ||
| Q1 25 | — | $0.47 | ||
| Q3 24 | — | $0.40 | ||
| Q2 24 | $-0.28 | $0.77 | ||
| Q1 24 | — | $0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $1.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $148.6M | $2.2B |
| 总资产 | $407.1M | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLLSEXEL
| Q1 26 | — | $1.1B | ||
| Q4 25 | — | $988.5M | ||
| Q3 25 | — | $791.1M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | $149.0M | $1.0B | ||
| Q1 24 | — | $963.3M |
股东权益CLLSEXEL
| Q1 26 | — | $2.2B | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.2B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | $148.6M | $2.1B | ||
| Q1 24 | — | $2.1B |
总资产CLLSEXEL
| Q1 26 | — | $2.8B | ||
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.9B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | $407.1M | $2.8B | ||
| Q1 24 | — | $2.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $333.5M |
| 自由现金流经营现金流 - 资本支出 | $27.6M | $332.4M |
| 自由现金流率自由现金流/营收 | 290.5% | 55.5% |
| 资本支出强度资本支出/营收 | 13.2% | 0.2% |
| 现金转化率经营现金流/净利润 | — | 1.36× |
| 过去12个月自由现金流最近4个季度 | — | $875.8M |
8季度趋势，按日历期对齐
经营现金流CLLSEXEL
| Q1 26 | — | $333.5M | ||
| Q4 25 | — | $290.3M | ||
| Q3 25 | — | $49.0M | ||
| Q2 25 | — | $211.4M | ||
| Q1 25 | — | $240.3M | ||
| Q3 24 | — | $271.3M | ||
| Q2 24 | $28.9M | $119.5M | ||
| Q1 24 | — | $68.8M |
自由现金流CLLSEXEL
| Q1 26 | — | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | — | $236.3M | ||
| Q3 24 | — | $263.1M | ||
| Q2 24 | $27.6M | $113.0M | ||
| Q1 24 | — | $59.1M |
自由现金流率CLLSEXEL
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 41.7% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | 290.5% | 17.7% | ||
| Q1 24 | — | 13.9% |
资本支出强度CLLSEXEL
| Q1 26 | — | 0.2% | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | 13.2% | 1.0% | ||
| Q1 24 | — | 2.3% |
现金转化率CLLSEXEL
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | 1.72× | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 1.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
